Q1 2020 13F Holders as of 3/31/2020
-
Type / Class
-
Equity / Common Stock, $0.01 par value per share
-
Shares outstanding
-
210M
-
Number of holders
-
127
-
Total 13F shares, excl. options
-
123M
-
Shares change
-
-14.6M
-
Total reported value, excl. options
-
$245M
-
Value change
-
-$37.6M
-
Put/Call ratio
-
0.14
-
Number of buys
-
75
-
Number of sells
-
-60
-
Price
-
$2.00
Significant Holders of BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) as of Q1 2020
163 filings reported holding BCRX - BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share as of Q1 2020.
BIOCRYST PHARMACEUTICALS INC - Common Stock, $0.01 par value per share (BCRX) has 127 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 123M shares
of 210M outstanding shares and own 58.46% of the company stock.
Largest 10 shareholders include BlackRock Inc. (13.4M shares), BAKER BROS. ADVISORS LP (10.9M shares), VANGUARD GROUP INC (8.77M shares), Eversept Partners, LP (7.54M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (7.5M shares), MILLENNIUM MANAGEMENT LLC (6.45M shares), CITADEL ADVISORS LLC (6.11M shares), STATE STREET CORP (5.75M shares), UBS Group AG (5.08M shares), and JANUS HENDERSON GROUP PLC (4.88M shares).
This table shows the top 127 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.